首页|On-demand transdermal insulin delivery system for type 1 diabetes therapy with no hypoglycemia risks
On-demand transdermal insulin delivery system for type 1 diabetes therapy with no hypoglycemia risks
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
Elsevier
Diabetes is a metabolic disease that is affecting an ever-increasing number of people worldwide, resulting in increased burdens on healthcare systems and societies. Constant monitoring of blood glucose levels is required to prevent serious or even deadly complications. One major challenge of diabetes management is the simple and timely administration of insulin to facilitate consistent blood glucose regulation and reduce the incidence of hypoglycemia. With this research, we construct an insulin delivery system, the delivery system is comprised of phenylboronic acid based fluorescent probes, which is used as glucose responsive linkers, mesoporous silica nanoparticles providing an insulin reservoir, and zinc oxide nanoparticles used as gate keepers. The system with glucose sensitive responsive linker exhibits controlled release of insulin under high glucose concentrations, providing prolonged blood glucose regulation and no risks of hypoglycemia. Furthermore, the system is combined with a hyaluronic-acid based microneedle patch, which exhibit efficient skin penetration for transdermal delivery. With our sys-tem, the nanoparticles provide outstanding in vivo glucose regulation when administrated by subcuta-neous injection or via transdermal microneedle patch. We anticipate that our biocompatible smart glucose responsive microneedle patch (SGRM patch) will facilitate the development of clinically useful systems. CO 2021 Elsevier Inc. All rights reserved.
NSTL
Elsevier
